Clinical Trials

View on ClinicalTrials.gov
Development Highlights
1. Triple-Pathway Approach:
Designed to activate GLP-1, GIP and FGF21 signaling, integrating complementary pathways involved in glucose regulation, energy balance and lipid metabolism.
2. Beyond Weight Management:
Designed to broaden the therapeutic potential of incretin-based approaches, with the aim of addressing both excess body weight and associated metabolic dysfunction.
3. Potential in Metabolic Liver Disease:
Preclinical findings support further investigation in obesity-associated metabolic liver disease, including potential effects on hepatic steatosis, inflammation and fibrosis.
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
